{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:32:18Z","timestamp":1768325538238,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,27]],"date-time":"2019-10-27T00:00:00Z","timestamp":1572134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013945","name":"Institut de Recherches Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.neuropharm.2019.107829","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T12:33:42Z","timestamp":1571920422000},"page":"107829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia"],"prefix":"10.1016","volume":"162","author":[{"given":"Ioannis","family":"Mantas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"Mannoury-la-cour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Millan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.107829_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-381328-2.00004-3","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"98","author":"Fisone","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2019.107829_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.biopha.2017.12.056","article-title":"Orphan G protein-coupled receptors: the role in CNS disorders","volume":"98","author":"Alavi","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"41","key":"10.1016\/j.neuropharm.2019.107829_bib3","doi-asserted-by":"crossref","first-page":"14057","DOI":"10.1523\/JNEUROSCI.1312-15.2015","article-title":"Modulation by trace amine-associated receptor 1 of experimental Parkinsonism, L-DOPA responsivity, and glutamatergic neurotransmission","volume":"35","author":"Alvarsson","year":"2015","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2019.107829_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/brain.2017.0486","article-title":"Remodeling of sensorimotor brain connectivity in Gpr88-deficient mice","volume":"7","author":"Arefin","year":"2017","journal-title":"Brain Connect."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.neuron.2018.01.006","article-title":"Dopamine's effects on corticostriatal synapses during reward-based behaviors","volume":"97","author":"Bamford","year":"2018","journal-title":"Neuron"},{"issue":"33","key":"10.1016\/j.neuropharm.2019.107829_bib7","doi-asserted-by":"crossref","first-page":"14845","DOI":"10.1073\/pnas.1009874107","article-title":"Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors","volume":"107","author":"Bateup","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107829_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations","volume":"20","author":"Bernheimer","year":"1973","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.neuropharm.2019.107829_bib9","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.107829_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nbd.2012.10.013","article-title":"Comparison of rating scales used to evaluate L-DOPAinduced dyskinesia in the 6-OHDA lesioned rat","volume":"50","author":"Breger","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.107829_bib11","doi-asserted-by":"crossref","first-page":"163171","DOI":"10.1016\/S0165-0270(02)00172-3","article-title":"Improved ceramic-based multisite microelectrode for rapid measurements of L-glutamate in the CNS","volume":"119","author":"Burmeister","year":"2002","journal-title":"J. Neurosci. Methods"},{"issue":"22","key":"10.1016\/j.neuropharm.2019.107829_bib12","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1523\/JNEUROSCI.20-22-08443.2000","article-title":"Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity","volume":"20","author":"Calabresi","year":"2000","journal-title":"J. Neurosci."},{"issue":"Pt 7","key":"10.1016\/j.neuropharm.2019.107829_bib13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2019.107829_bib14","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.parkreldis.2008.04.023","article-title":"Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence","volume":"14","author":"Carta","year":"2008","journal-title":"Park. Relat. Disord."},{"issue":"8","key":"10.1016\/j.neuropharm.2019.107829_bib15","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107829_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.07.002","article-title":"Expanding the repertoire of L-DOPA's actions: a comprehensive review of its functional neurochemistry","volume":"151","author":"De Deurwaerd\u00e8re","year":"2017","journal-title":"Prog. Neurobiol."},{"issue":"12","key":"10.1016\/j.neuropharm.2019.107829_bib17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease","volume":"26","author":"Duty","year":"2012","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib18","first-page":"1275","article-title":"Mapping GPR88-Venus illuminates a novel role for GPR88 in sensory processing. Brain Struct Funct","volume":"223","author":"Ehrlich","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.107829_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34","author":"Gerfen","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2019.107829_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1460-9568.2008.06387.x","article-title":"Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms","volume":"28","author":"Giorgi","year":"2008","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.107829_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1124\/jpet.107.131698","article-title":"Second-by-second measures of L-glutamate in the prefrontal cortex and striatum of freely moving mice","volume":"324","author":"Hascup","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107829_bib22","doi-asserted-by":"crossref","first-page":"16081620","DOI":"10.1111\/j.1471-4159.2010.07066.x","article-title":"Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex","volume":"115","author":"Hascup","year":"2010","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib23","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1016\/S0960-9822(97)70073-3","article-title":"Synaptic plasticity: a role for nitric oxide in LTP","volume":"7","author":"Huang","year":"1997","journal-title":"Curr. Biol."},{"issue":"6","key":"10.1016\/j.neuropharm.2019.107829_bib24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/bmc.1338","article-title":"Determination of dopamine, serotonin, and their metabolites in pediatric cerebrospinal fluid by isocratic high performance liquid chromatography coupled with electrochemical detection","volume":"24","author":"Hubbard","year":"2010","journal-title":"Biomed. Chromatogr."},{"issue":"7","key":"10.1016\/j.neuropharm.2019.107829_bib25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/cn500082p","article-title":"Synthesis, pharmacological characterization, and structure-activity relationship studies of small molecular agonists for the orphan GPR88 receptor","volume":"5","author":"Jin","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"10","key":"10.1016\/j.neuropharm.2019.107829_bib26","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1021\/acschemneuro.6b00182","article-title":"Effect of substitution on the aniline moiety of the GPR88 agonist 2-PCCA: synthesis, structure-activity relationships, and molecular modeling studies","volume":"7","author":"Jin","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"15","key":"10.1016\/j.neuropharm.2019.107829_bib27","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1021\/acs.jmedchem.8b00566","article-title":"Discovery of a potent, selective, and brain-penetrant small molecule that activates the orphan receptor GPR88 and reduces alcohol intake","volume":"61","author":"Jin","year":"2018","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.neuropharm.2019.107829_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/187152709789824606","article-title":"Glutamate receptors as therapeutic targets for Parkinson's disease","volume":"8","author":"Johnson","year":"2009","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib29","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1046\/j.1471-4159.1994.63030972.x","volume":"63","author":"Karoum","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2019.107829_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nbd.2014.06.013","article-title":"RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease","volume":"70","author":"Ko","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.107829_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0306-4522(83)90102-1","article-title":"The striatal cholinergic interneuron: synaptic tarhet of dopaminergic terminals?","volume":"10","author":"Lehmann","year":"1983","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.neuropharm.2019.107829_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neuron.2011.11.015","article-title":"RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits","volume":"73","author":"Lerner","year":"2012","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107829_bib33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.mcn.2009.09.007","article-title":"The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?","volume":"42","author":"Logue","year":"2009","journal-title":"Mol. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107829_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","article-title":"A model of L-DOPA-induced dyskinesia in 6hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function","volume":"16","author":"Lundblad","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107829_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","article-title":"Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia","volume":"194","author":"Lundblad","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107829_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12473","article-title":"Lack of anticipatory behavior in Gpr88 knockout mice showed by automatized home cage phenotyping","author":"Maroteaux","year":"2018","journal-title":"Genes Brain Behav."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1460-9568.2009.06842.x","article-title":"Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents","volume":"30","author":"Massart","year":"2009","journal-title":"Eur. J. Neurosci."},{"issue":"14","key":"10.1016\/j.neuropharm.2019.107829_bib38","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1002\/cne.23991","article-title":"Developmental and adult expression patterns of the G-protein-coupled receptor GPR88 in the rat: establishment of a dual nuclear-cytoplasmic localization","volume":"524","author":"Massart","year":"2016","journal-title":"J. Comp. Neurol."},{"issue":"11","key":"10.1016\/j.neuropharm.2019.107829_bib39","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.biopsych.2015.05.020","article-title":"Mice lacking GPR88 show motor deficit, improved spatial learning, and low anxiety reversed by delta opioid antagonist","volume":"79","author":"Meirsman","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107829_bib40","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0202-16.2016","article-title":"GPR88 in A2AR neurons enhances anxiety-like behaviors","volume":"3","author":"Meirsman","year":"2016","journal-title":"eNeuro"},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107829_bib41","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/ejn.13646","article-title":"GPR88 in A(2A) receptor-expressing neurons modulates locomotor response to dopamine agonists but not sensorimotor gating","volume":"46","author":"Meirsman","year":"2017","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/geno.2000.6340","article-title":"A novel G-protein-coupled receptor gene expressed in striatum","volume":"69","author":"Mizushima","year":"2000","journal-title":"Genomics"},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.conb.2011.04.004","article-title":"Cholinergic modulation of synaptic integration and dendritic excitability in the striatum","volume":"21","author":"Oldenburg","year":"2011","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2019.107829_bib44","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"issue":"6","key":"10.1016\/j.neuropharm.2019.107829_bib45","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/mds.27261","article-title":"Motor complications in Parkinson's disease: striatal molecular and electrophysiological mechanisms of dyskinesias","volume":"33","author":"Picconi","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107829_bib46","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.neuropharm.2019.107829_bib47","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.neuropharm.2019.107829_bib48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/nn.3239","article-title":"Lack of GPR88 enhances medium spiny neuron activity and alters motor- and cue-dependent behaviors","volume":"15","author":"Quintana","year":"2012","journal-title":"Nat. Neurosci."},{"issue":"33","key":"10.1016\/j.neuropharm.2019.107829_bib49","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1523\/JNEUROSCI.2439-16.2017","article-title":"Striatal GPR88 modulates foraging efficiency","volume":"37","author":"Rainwater","year":"2017","journal-title":"J. Neurosci."},{"issue":"2223","key":"10.1016\/j.neuropharm.2019.107829_bib50","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/S0024-3205(01)01055-4","article-title":"Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism","volume":"68","author":"Salamone","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2019.107829_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neuint.2014.10.004","article-title":"Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?","volume":"79","author":"Sancesario","year":"2014","journal-title":"Neurochem. Int."},{"issue":"5","key":"10.1016\/j.neuropharm.2019.107829_bib52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1073\/pnas.1524303113","article-title":"p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism","volume":"113","author":"Schintu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107829_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","article-title":"Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP","volume":"318","author":"Schober","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2019.107829_bib54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fneur.2018.00524","article-title":"Opioidergic modulation of striatal circuits, implications in Parkinson's disease and levodopa induced dyskinesia","volume":"9","author":"Sgroi","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107829_bib55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.expneurol.2016.03.024","article-title":"Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats","volume":"280","author":"Sgroi","year":"2016","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107829_bib56","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neuron.2015.10.039","article-title":"M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia","volume":"88","author":"Shen","year":"2015","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.neuropharm.2019.107829_bib57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/cercor\/bhs342","article-title":"Anatomic and molecular development of corticostriatal projection neurons in mice","volume":"24","author":"Sohur","year":"2014","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2019.107829_bib58","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1038\/tp.2014.39","article-title":"NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum","volume":"4","author":"Stan","year":"2014","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib59","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0306-4522(97)00046-8","article-title":"Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens","volume":"79","author":"Svenningsson","year":"1997","journal-title":"Neuroscience"},{"issue":"Pt 4","key":"10.1016\/j.neuropharm.2019.107829_bib60","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/brain\/awu409","article-title":"Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study","volume":"138","author":"Svenningsson","year":"2015","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107829_bib63","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","article-title":"Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. . 1970 Dec 18;24(3):485-93.","volume":"24","author":"Ungerstedt","year":"1970","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2019.107829_bib61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/978-1-61779-328-8_27","article-title":"Determination of neurotransmitter levels in models of Parkinson's disease by HPLC-ECD","volume":"793","author":"Yang","year":"2011","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"10.1016\/j.neuropharm.2019.107829_bib62","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.0711839105","article-title":"Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819303958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819303958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:58:00Z","timestamp":1758437880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819303958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":62,"alternative-id":["S0028390819303958"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107829","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107829"}}